SynAct Pharma AB

SynAct Pharma AB

1.23
EUR
-0.06
(-4.52%)
-0.17EPS
86.69MMarket Cap
Feb 18Next Earn

Total Valuation

EUR

As of September 30, 2026, SynAct Pharma AB carries a market capitalization of 86.69M, placing it among publicly traded companies globally. Its enterprise value stands at 86.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap86.69M
Enterprise Value86.96M

Important Dates

SynAct Pharma AB's next confirmed earnings release is scheduled for February 18, 2027.

Earnings Date2/18/2027

Share Statistics

As of September 30, 2026, SynAct Pharma AB has 56.00M shares outstanding.

Shares Outstanding56.00M

Valuation Ratios

These figures are as of September 30, 2026.

PB Ratio6.92
P/TBV Ratio-42.70
P/FCF Ratio-8.73
P/OCF Ratio-8.73

Financial Position

As of September 30, 2026, SynAct Pharma AB maintains a current ratio of 4.79, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.

Current Ratio4.79
Quick Ratio3.29
Debt / Equity32.08
Debt / EBITDA-0.42

Financial Efficiency

These figures cover the twelve months ended September 30, 2026. The company generates approximately - - in revenue per employee across its workforce of 8.00, a quick read on workforce productivity versus industry peers.

Employee Count8.00

Taxes

EUR

Over the twelve months ended September 30, 2026, SynAct Pharma AB recorded an income tax benefit of -704,693.71 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -9.76M and -9.05M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-704,693.71

Stock Price Statistics

EUR

These figures are as of the close on November 17, 2026.

50-Day Moving Average1.52

Income Statement

EUR

Over the twelve months ended September 30, 2026, SynAct Pharma AB generated - - in revenue and converted that into -9.05M in net income, yielding earnings per share of -0.17. EBITDA reached -9.52M, while operating income came in at -9.52M.

Operating Income-9.52M
Pretax Income-9.76M
Net Income-9.05M
EBITDA-9.52M
EBIT-9.52M
Earnings Per Share (EPS)-0.17

Balance Sheet

EUR

As of September 30, 2026, SynAct Pharma AB holds 3.74M in cash and equivalents against 4.02M in total debt, resulting in a net debt position of 209,987.61. Total book value stands at 12.52M, with working capital of 4.31M providing operational flexibility.

Cash & Cash Equivalents3.74M
Total Debt4.02M
Net Debt209,987.61
Equity (Book Value)12.52M
Book Value Per Share0.22
Working Capital4.31M

Cash Flow

EUR

SynAct Pharma AB produced -9.72M in operating cash flow over the twelve months ended September 30, 2026.

Operating Cash Flow-9.72M
Free Cash Flow-9.72M
FCF Per Share-0.18

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -11.45: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.99, meaning SynAct Pharma AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-8.99
FCF Yield-11.45

Stock Splits

SynAct Pharma AB's most recent stock split took place on December 16, 2024.

Last Split Date12/16/2024

Scores

As of September 30, 2026, SynAct Pharma AB has an Altman Z-Score of -14.55, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-14.55